The advent of ‘big data’ and modern analytics mandates a change of scale in every aspect of the biomedical enterprise. These forces are realigning academic medicine and traditional industrial partners, and also creating the context for an emerging new ecosystem for discovery, translation, care and implementation that promises to transform and integrate all these areas of endeavour.
This is a preview of subscription content, log in via an institution to check access.
References
Schwab, K. The fourth industrial revolution: what it means and how to respond. Foreign Affairs https://www.foreignaffairs.com/articles/2015-12-12/fourth-industrial-revolution (2015).
MacRae, C. A., Roden, D. M. & Loscalzo, J. The future of cardiovascular therapeutics. Circulation 133, 2610–2617 (2016).
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
Acknowledgements
C.A.M. is funded by The Burroughs Wellcome Foundation, the NIH and by awards from the AHA, AstraZeneca, Quest Diagnostics and Verily Life Sciences.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
MacRae, C.A. Evolution of academic–industry partnerships in cardiovascular research and development. Nat Rev Cardiol 16, 449–451 (2019). https://doi.org/10.1038/s41569-019-0223-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-019-0223-0
- Springer Nature Limited